Literature DB >> 24678406

Generation and characterization of neutralizing monoclonal antibodies against baculo-expressed HPV 16 VLPs.

P Vidyasagar1, V N Sridevi1, S Rajan1, A Praveen1, A Srikanth1, G Abhinay1, V Siva Kumar1, R R Verma1, L Rajendra1.   

Abstract

Human papillomavirus (HPV) is the well-known second most cause of cervical cancer in women worldwide. According to the WHO survey, 70% of the total cervical cancers are associated with types HPV 16 and 18. Presently used prophylactic vaccine for HPV contains mainly capsid protein of L1 virus like particles (VLPs). Correct folding of VLPs and display of neutralizing epitopes are the major constraint for VLP-based vaccines. Further, monoclonal antibodies (mAbs) play a vital role in developing therapeutics and diagnostics. mAbs are also useful for the demonstration of VLP conformation, virus typing and product process assessment as well. In the present study, we have explored the usefulness of mAbs generated against sf-9 expressed HPV 16 VLPs demonstrated as type-specific and conformational dependent against HPV 16 VLPs by ELISA. High affinity and high pseudovirion neutralization titer of mAbs indicated their potential for the development of prophylactic vaccines for HPV. Also, the type-specific and conformational reactivity of the mAbs to HPV 16 VLPs in sf-9 cells by immunofluorescence assay proved their diagnostic potential.

Entities:  

Keywords:  HPV 16 VLP; monoclonal antibody; pseudovirus neutralization assay

Year:  2014        PMID: 24678406      PMCID: PMC3955832          DOI: 10.1556/EuJMI.4.2014.1.5

Source DB:  PubMed          Journal:  Eur J Microbiol Immunol (Bp)        ISSN: 2062-509X


  33 in total

1.  Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types.

Authors:  Raeda Z Rizk; Neil D Christensen; Kristina M Michael; Martin Müller; Peter Sehr; Tim Waterboer; Michael Pawlita
Journal:  J Gen Virol       Date:  2008-01       Impact factor: 3.891

2.  Baculovirus expression of the human papillomavirus type 16 capsid proteins: detection of L1-L2 protein complexes.

Authors:  S Z Xi; L M Banks
Journal:  J Gen Virol       Date:  1991-12       Impact factor: 3.891

3.  Immunological analyses of human papillomavirus capsids.

Authors:  T Giroglou; M Sapp; C Lane; C Fligge; N D Christensen; R E Streeck; R C Rose
Journal:  Vaccine       Date:  2001-02-08       Impact factor: 3.641

4.  Interlaboratory agreement among results of human papillomavirus type 16 enzyme-linked immunosorbent assays.

Authors:  H D Strickler; A Hildesheim; R P Viscidi; K V Shah; B Goebel; J Drummond; D Waters; Y Sun; N L Hubbert; S Wacholder; L A Brinton; C L Han; P C Nasca; R McClimens; K Turk; V Devairakkam; S Leitman; C Martin; J T Schiller
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

5.  Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16.

Authors:  X S Chen; R L Garcea; I Goldberg; G Casini; S C Harrison
Journal:  Mol Cell       Date:  2000-03       Impact factor: 17.970

6.  Generation of HPV pseudovirions using transfection and their use in neutralization assays.

Authors:  Christopher B Buck; Diana V Pastrana; Douglas R Lowy; John T Schiller
Journal:  Methods Mol Med       Date:  2005

7.  In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.

Authors:  R B Roden; H L Greenstone; R Kirnbauer; F P Booy; J Jessie; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

8.  Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.

Authors:  N D Christensen; N M Cladel; C A Reed; L R Budgeon; M E Embers; D M Skulsky; W L McClements; S W Ludmerer; K U Jansen
Journal:  Virology       Date:  2001-12-20       Impact factor: 3.616

9.  Identification of human papillomavirus seroconversions.

Authors:  A Wikström; G J van Doornum; W G Quint; J T Schiller; J Dillner
Journal:  J Gen Virol       Date:  1995-03       Impact factor: 3.891

Review 10.  HPV & head and neck cancer: a descriptive update.

Authors:  Peter K C Goon; Margaret A Stanley; Jörg Ebmeyer; Lars Steinsträsser; Tahwinder Upile; Waseem Jerjes; Manuel Bernal-Sprekelsen; Martin Görner; Holger H Sudhoff
Journal:  Head Neck Oncol       Date:  2009-10-14
View more
  2 in total

Review 1.  Current Status and Perspective on the Use of Viral-Based Vectors in Eukaryotic Microalgae.

Authors:  Omayra C Bolaños-Martínez; Ganesan Mahendran; Sergio Rosales-Mendoza; Sornkanok Vimolmangkang
Journal:  Mar Drugs       Date:  2022-06-29       Impact factor: 6.085

Review 2.  Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV and HPV.

Authors:  Braira Wahid; Amjad Ali; Muhammad Idrees; Shazia Rafique
Journal:  Cell Immunol       Date:  2016-08-03       Impact factor: 4.868

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.